Episeize 500 Tablet contains Levetiracetam 500 mg, an antiepileptic medication indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and preventing seizure propagation. Episeize 500 is typically prescribed as adjunctive therapy in adults and pediatric patients aged four years and above. The tablet should be administered orally, with or without food, as directed by a healthcare professional. Dosage adjustments may be necessary based on clinical response and tolerability, with careful consideration in patients with renal impairment. Common adverse effects include somnolence, dizziness, fatigue, and behavioral changes such as irritability or agitation, which generally diminish with continued use. Episeize 500 should be used cautiously in patients with a history of psychiatric disorders or suicidal ideation. Regular monitoring and follow-up are essential to evaluate therapeutic efficacy and safety. This medication should not be discontinued abruptly to avoid increased seizure frequency. Episeize 500 Tablet offers a well-tolerated and effective option for seizure management within a comprehensive epilepsy treatment plan.